Dihexa
Desired outcomes, not effects demonstrated in humans.
The available data are essentially preclinical.
Efficacy and safety in humans have not been established.
Dihexa is a synthetic compound derived from angiotensin IV and studied as a positive modulator of hepatocyte growth factor (HGF)/c-Met signaling. The c-Met receptor participates in context-dependent cellular signaling, including pathways involving PI3K/AKT and MAPK/ERK. Preclinical research has explored synaptogenesis, dendritic spines and neural plasticity; however, clinical efficacy and safety have not been established in humans. DIHEXA is not presented as a medicine. For laboratory research use only. Not for human consumption.
Dihexa has been studied as a positive modulator of HGF/c-Met signaling in preclinical experimental systems.
c-Met is a receptor tyrosine kinase associated with cellular growth, survival, motility and differentiation signaling.
Research has explored PI3K/AKT as one downstream pathway associated with HGF-driven c-Met activation.
MAPK/ERK signaling is also investigated downstream of c-Met in model-dependent cellular responses.
A synthetic research compound developed from angiotensin IV-related chemistry.
Preclinical models suggest associations with the formation of new synaptic connections.
Research has explored changes in neuronal protrusions involved in synaptic connectivity.
Experimental work investigates model-specific adaptation of neuronal structure and signaling.
Human clinical efficacy and safety have not been established.
How to prepare your peptide safely.
PDF GuideRecommended research dosage protocols.
PDF GuideLatest clinical research and key findings.
PDF GuideSimple visual explanation of how it works.
PDF GuideDihexa is a peptidomimetic compound derived from research on angiotensin IV. It is studied in preclinical models concerning neuronal plasticity, among other topics.
A peptidomimetic is a molecule designed to reproduce certain properties of a peptide with a modified structure. The term describes a design approach; it does not demonstrate clinical efficacy.
The HGF growth-factor and c-Met receptor pathway was proposed to explain its activity. However, a frequently cited paper on this mechanism was retracted in 2025. It must therefore be presented as a hypothesis whose strength requires reassessment, not as an established mechanism.
Synaptogenesis is the formation of connections between neurons. The term appears in preclinical Dihexa publications, some of whose data must be reassessed in light of the cited retraction. It does not support a conclusion of improved human memory.
No. Preclinical observations must be distinguished from controlled human-study results. The product page must not present Dihexa as a cognitive enhancer with demonstrated efficacy.
This pathway is also involved in the growth and function of different cells. Presenting it only as a mechanism that is “beneficial for the brain” would omit important biological context.
Review the analytical documentation available for the batch and confirm that it matches the reference ordered. Identity, purity and quantity are different pieces of information. A purity percentage alone does not establish sterility or the absence of endotoxins.
Follow the conditions on the label and in the batch documentation, together with your laboratory’s validated procedures. Conditions for a lyophilized powder may differ from those for a solution. Without reference-specific data, do not infer stability from another product.
No. This reference is intended for laboratory research, not human consumption or personal medical use. Scientific explanations are not prescriptions, and the quantities shown per vial are not usage doses.